Follow on Google News News By Tag * Foam * Pharmaceutical * Topical * Drug * Aerosol Foam * Dermatology * Gynecology * Ophthalmology * Patents * Alpha Hydroxy Acids * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Foamix Receives a New U.S. Patent for its Emollient and Aqueous Foam TechnologyThe Patent Covers Foams with Urea, Lactic Acid, Salicylic Acid and Penetration Enhancers
By: Foamix Ltd United States Patent No. 7,700,076, entitled “Penetrating pharmaceutical foam” covers unique emollient foam compositions and aqueous foam compositions that can be used to deliver a wide range of actives having activity against many diseases and disorders. "Foamix continually strives to strengthen and expand its intellectual property position, which is a key aspect to our business and competitive position. The grant of this U.S. patent is the result of extensive ongoing efforts to develop a stream of innovative products and technologies for the dermatology and gynecology markets that provide enhanced efficacy and consumer satisfaction," The patent claims foam compositions comprising urea, alpha-hydroxy acids (such as lactic acid and glycolic acid) and beta-hydroxy acids, e.g., salicylic acid, which are keratolytic. The granted claims are further directed to foam compositions that contain skin penetration enhancers, including inter alia propylene glycol, glycerol, dimethyl isosorbide, and certain polyethylene glycol PEG polymers. The claims also cover a variety of drugs that can additionally be incorporated in such compositions, including antibacterial agents, antifungals, antiviral agents, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-allergic agents, anticancer agents, local anesthetics, retinoids, photodynamic therapy agents, anti-wrinkle agents, skin whitening agents, immunosuppressants and immunomodulators. About Foamix Ltd. Headquartered in Rehovot, Israel, Foamix Ltd. is a leading developer of topical foam and Oil Gel™ formulations, which can be used for dermatological, gynecological and ophthalmic applications. Foamix’s state-of-the- To date, Foamix has twenty two issued patents worldwide covering its foam and OilGel™ technology platforms, including 8 issued patents in the United States. The company further has over 150 pending patent applications worldwide, of which more than 50 are filed in the U.S. For additional information please see: www.foamix.co.il For more information, please contact: Dov Tamarkin, Foamix Ltd, +972-8-9316233 or dov@foamix.co.il. End
Account Email Address Disclaimer Report Abuse
|
|